A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.

ABSTRACT:

Background

Hepatitis is a common adverse effect of antituberculosis drugs. Silymarin prevented drug-induced hepatoxicity in animals with anti-oxidative mechanisms but its effect in human has been unknown. We aimed to evaluate the efficacy of silymarin for preventing antituberculosis-drug induced liver injury (antiTB-DILI) in patients with tuberculosis.

Methods

A double-blind randomized placebo-controlled trial was performed. Tuberculosis patients were randomly allocated to receive placebo or silymarin. The outcomes of interests were antiTB-DILI and the maximum liver enzymes at week 4. Antioxidative enzymes (i.e., superoxide dismutase (SOD), glutathione and malondialdehyde assays) were assessed. The risks of antiTB-DILI between the two groups were compared. A number need to t

SUBMITTER: Luangchosiri C 

PROVIDER: S-EPMC4580123 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature